Sales of KRW 1.2983 Trillion and Operating Profit of KRW 486.7 Billion
Samsung Biologics achieved its highest-ever quarterly results in the first quarter of this year. This performance was driven by the full-scale revenue contribution from Plant 4 and robust sales of biosimilars, despite the threats posed by the global economic downturn and protectionism.
On April 23, Samsung Biologics announced through a regulatory filing that its consolidated revenue for the first quarter of this year reached KRW 1.2983 trillion, with operating profit of KRW 486.7 billion.
On a standalone basis, Samsung Biologics reported revenue of KRW 999.5 billion and operating profit of KRW 430.1 billion, based on full-capacity operations at Plants 1 to 3, stable ramp-up at Plant 4, and favorable foreign exchange rates. Samsung Bioepis recorded revenue of KRW 400.6 billion and operating profit of KRW 128 billion by expanding sales of biosimilar products in the global market.
Previously, in January, Samsung Biologics presented a sales growth guidance of 20-25% year-on-year for 2025. In its first-quarter earnings announcement, Samsung Biologics maintained the sales growth guidance set at the beginning of the year, taking into comprehensive consideration uncertainties such as changes in the global economic environment and exchange rate fluctuations.
As of the end of the first quarter this year, Samsung Biologics reported consolidated assets of KRW 17.437 trillion, equity of KRW 11.2801 trillion, and liabilities of KRW 6.1569 trillion. The company also maintained a stable financial position, with a debt ratio of 54.6% and a borrowing ratio of 11.9%.
Samsung Biologics plans to maximize customer satisfaction and sustain its growth by strengthening its three-pronged expansion strategy?production capacity, portfolio, and global presence?along with its core management values known as '4E': Customer Excellence, Operational Excellence, Quality Excellence, and People Excellence.
Earlier this month, the company began operations at its fifth plant, which has a capacity of 180,000 liters, bringing Samsung Biologics' total production capacity to 784,000 liters. Starting with Plant 5, Samsung Biologics plans to add three more plants to its second Bio Campus by 2032, securing a total production capacity of 1,324,000 liters and thereby maintaining a significant global production capacity lead.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
